Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
University of Kansas Medical Center
Seagen Inc.
M.D. Anderson Cancer Center
Sun Yat-sen University
University Health Network, Toronto
University Health Network, Toronto
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Duke University
M.D. Anderson Cancer Center
Arcus Biosciences, Inc.
Ascendis Pharma A/S
Qurient Co., Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
Institute of Cancer Research, United Kingdom
AbbVie
AstraZeneca
National Institutes of Health Clinical Center (CC)
University of Oklahoma
Jonsson Comprehensive Cancer Center
University of Kansas Medical Center
City of Hope Medical Center
Beth Israel Deaconess Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Indiana University
University of Rochester
ImmunityBio, Inc.
Beth Israel Deaconess Medical Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Huazhong University of Science and Technology
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Université de Sherbrooke
University of Kentucky
HiFiBiO Therapeutics
Akeso
TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
Weill Medical College of Cornell University
National Cancer Institute (NCI)
Mayo Clinic
M.D. Anderson Cancer Center